Skip to main content
. Author manuscript; available in PMC: 2019 Jul 31.
Published in final edited form as: Circulation. 2018 Jul 31;138(5):513–526. doi: 10.1161/CIRCULATIONAHA.117.031635

Figure 5. Endoglin Negatively Regulates BMP9 Expression in Cardiac Fibroblasts and Heart Failure.

Figure 5

A) Representative immunoblots and quantitation of BMP9 expression normalized to β-actin expression in human cardiac fibroblasts following knockdown of Endoglin expression (siEndoglin) compared to scrambled siRNA (scr-siRNA) with and without TGF-β1 stimulation. B) Representative immunoblots and quantitation of BMP9 expression normalized to β-actin expression in human cardiac fibroblasts following treatment with a neutralizing endoglin antibody (Eng NAb) compared to isotype control (IgG) with and without TGF-β1 stimulation. C) Representative immunoblots and quantitation of LV BMP9 expression normalized to GAPDH expression following two weeks of TAC in WT and Eng+/− mice. Data expressed as fold change vs. Control or Sham. All p values<0.05. Panel A: *, vs. Control scr-siRNA; †, vs. Control siEndoglin. Panel B: p<0.05: *, vs. Control IgG; †, vs. Control NAb Eng. Panel C: *, vs. WT Sham; †, vs. Eng+/− Sham; ‡, vs. WT TAC.